Skip to main
  1. Stocks
  2. Prenetics Global Ltd
  3. Forecast
PRE

PRE Stock Forecast & Price Target

PRE Analyst Ratings

Based on 6 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Prenetics Global is supported by a large $1 billion growth financing from General Catalyst’s Customer Value Fund, which can fund up to 70% of IM8 marketing spend for 25 months without dilution and materially reduces balance-sheet risk. Its IM8 brand is scaling rapidly, with preliminary June revenue of about $17 million, 1Q26 revenue from continuing operations of $36 million up roughly 333% year over year, ARR near $200 million as of May 31, and FY26 revenue guidance raised to $210-$220 million. The bull case is further strengthened by strong unit economics, including a 3:1 LTV/CAC, a shift toward quarterly subscriptions that improved AOV to $240 and speeds cash collection 3x, plus clinically validated products, broad global distribution to 43 markets, and expanding product adjacencies.

Bears say

Prenetics Global is viewed negatively because its growth depends heavily on retaining subscribers and converting new customers into recurring plans, yet renewal rates, order frequency, and customer lifetime value may deteriorate if consumer preferences shift or discretionary spending weakens. The company’s largest expense is sales and marketing, and while the move toward quarterly subscriptions may improve lifetime value, it also raises acquisition costs on an absolute basis, while global shipping, warehousing, tariffs, and trade restrictions add further pressure on margins and operating results. Governance and regulatory risks also weigh on the outlook, as the company is a controlled foreign private issuer with over 50% voting power held by the Chairman and CEO, while dietary supplements face intense competition and are not FDA-approved.

PRE has been analyzed by 6 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Prenetics Global Ltd and is not a guaranteed prediction by Public.com or investment advice.

PRE Analyst Forecast & Price Prediction

Get the latest PRE stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in PRE

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Prenetics Global Ltd (PRE) Forecast

Analysts have given PRE a Strong Buy based on their latest research and market trends.

According to 6 analysts, PRE has a Strong Buy consensus rating as of Nov 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $39.17, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $39.17, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Prenetics Global Ltd (PRE)


PRE Analyst Forecast & Price Prediction

Get the latest PRE stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in PRE

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover PRE stock data and trends